Alzheimer’s Association

Funders and NGOs find new reporting standards favorable

Tuesday, May 30, 2017

According to the World Health Organization (WHO), some of the world’s largest funders of medical research and international non-governmental organizations (NGOs) recently agreed on new standards for clinical trials outcomes. Funded all clinical trials, per these new standards, are required to be registered with all results publicly disclosed. By all indications, funders and NGOs who agreed to the new standards find the new requirements favorable.

[Read More]

NIH award expands landmark Alzheimer’s biomarker study

Tuesday, September 13, 2016

The Alzheimer’s Disease Neuroimaging Initiative (ADNI)—the long-running NIH-supported study investigating brain and fluid biomarkers of the disease—enters a new phase of discovery with the launch of ADNI3. With the recent NIH award of approximately $40 million over the next five years—coupled with anticipated private sector contributions of $20 million through the Foundation for the National Institutes of Health (FNIH)—ADNI3 will use cutting-edge technologies in brain imaging as it recruits hundreds of new volunteers. Expansion of the groundbreaking study, now in its 12th year, will further develop ways to speed clinical trials by providing researchers the biomarkers needed to detect the onset and track the progression of Alzheimer’s disease.

[Read More]

NIH-led effort launches Big Data portal for Alzheimer’s drug discovery

Friday, March 6, 2015

A NIH-led public-private partnership to transform and accelerate drug development has launched a new Alzheimer’s Big Data portal—including delivery of the first wave of data—for use by the research community. The new data sharing and analysis resource is part of the Accelerating Medicines Partnership (AMP), an unprecedented venture bringing together NIH, FDA, industry and academic scientists from a variety of disciplines to translate knowledge faster and more successfully into new therapies.

[Read More]

Neuro-MAP, MRC Technology to jumpstart drug development for brain diseases

Wednesday, November 19, 2014

Drugs for brain diseases such as dementia, motor neurone disease and Parkinson’s, which have stalled in development, could be revived thanks to up to $47.1 million in funding and resources from a global coalition of charities and funders. The Neurodegeneration Medicines Acceleration Program (Neuro-MAP), led by U.K. medical research charity MRC Technology, will help charities and funding bodies identify promising drug projects no longer in development and help scientists take them forward to the next stage.

[Read More]

National Alzheimer’s Plan milestones must be strengthened to meet 2025 goal

Wednesday, October 22, 2014

The U.S. government has initiated a major effort to prevent and effectively treat Alzheimer’s disease by 2025. However, a workgroup of nearly 40 Alzheimer’s researchers and scientists said the research milestones in the U.S. government’s National Plan to Address Alzheimer’s Disease must be broadened in scope, increased in scale and adequately funded in order to successfully achieve this goal. A series of proposals by the workgroup to enlarge and strengthen the plan have been published in Alzheimer’s & Dementia: the Journal of the Alzheimer’s Association.

[Read More]

Alzheimer’s Association articles call for global research collaboration

Friday, July 19, 2013

A global, collaborative research effort based on public-private partnerships, similar to the projects in the 1950s and 1960s that successfully reduced polio worldwide, will advance the prevention, diagnosis and treatment of Alzheimer’s disease, according to two articles written by leaders of the Alzheimer’s Association and published in the July issue of Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association.

[Read More]